The US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The indication is for patients who have previously received one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy in the unresectable locally advanced or metastatic setting.
Neladalkib is an ALK-selective TKI designed to help address treatment resistance and disease that has spread to the brain in ALK-positive NSCLC and other cancers.
The accelerated approval is largely based on results from the phase 1/2 ALKOVE-1 clinical trial (NCT05384626). In that trial, patients previously treated with alectinib as their only prior ALK TKI were given neladalkib and the confirmed overall response rate (ORR) was 49%, with a duration of response (DOR) of 6 or more months in 76% of responders and 12 or more months in 52% of responders. For patients with two or more prior ALK TKIs and chemotherapy, the ORR was 32%, with DOR of 6 or more months in 69% of responders and 12 or more months in 51% of responders.
Among patients with measurable central nervous system metastases at baseline, intracranial ORR was 55% (including 25% complete responses) in those previously treated with alectinib as their only prior ALK TKI, and 26% (including 11% complete responses) in those who had received two or more prior ALK TKIs and chemotherapy.
The most common adverse reactions were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. Permanent discontinuation of neladalkib due to adverse reactions occurred in 5% of patients, most frequently, hepatotoxicity.
Since the therapy was given accelerated approval, a full approval will require that meladalkib be further studied to confirm its clinical benefit.
For more information, visit https://www.gsk.com/en-gb/media/press-releases/nelkarmi-neladalkib-approved-in-the-us-for-previously-treated-advanced-alk-positive-non-small-cell-lung-cancer/
To learn more about NSCLC and other rare cancers, visit https://checkrare.com/diseases/cancers/
